“Real-World Achievement of Skin Clearance Targets and Improved Quality of Life With Risankizumab in Psoriasis Patients With Moderate Skin Involvement (BSA ≥ 3–10%)”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s421. Accessed May 18, 2025. https://skin.dermsquared.com/skin/article/view/3087.